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N-methyl-N-nitrosourea (MNU) induces estrogen-dependent mammary tumors in female Lewis rats. We explored the
antineoplastic activity of a synthetic androstane derivative, 17α-ethynyl-5α-androstane-3α,1 7 β-diol (HE3235), as a single agent
or in combination with docetaxel compared to tamoxifen, anastrazole, and docetaxel monotherapies against MNU-induced
mammarytumorsinfemaleLewisrats.TreatmentwithHE3235alonerapidlyreduced tumorburden,similarineﬀect to tamoxifen
and anastrozole.The combination of HE3235 with docetaxel was more eﬀective than any single agent, although without apparent
toxicity. Only HE3235 or HE3235 plus docetaxel continued to suppress tumor growth after cessation of treatment. HE3235
treatment increased immunohistochemicalmarkers of apoptosis and expression of proapoptotic genes and estrogen receptor beta
and decreased expression of antiapoptotic genes, androgen receptor, and estrogen receptor alpha. These data warrant clinical
investigation of HE3235 for breast cancer treatment.
1.Introduction
Breast cancer is one of the most common cancers among
women, and the incidence of breast cancer is increasing
worldwide [1].Approximately200,000womenarediagnosed
with breast cancer annually, with an associated mortality of
40,000intheUnitedStates[2].Currently,there are fewtreat-
mentsforhormone-dependentbreastcancer,withtamoxifen
and anastrazole being the most widely used therapies [3].
Although generally well tolerated, these treatments can be
associated with signiﬁcant morbidity [4], and development
of resistance is common [5, 6].
The carcinogen N-methyl-N-nitrosourea (MNU) induc-
es hormone-dependent mammary tumors in rats. This
model has previously been used to develop tamoxifen
therapy in women with breast cancer [7], and is considered
to be appropriate for studies of novel compounds potentially
usefulforthetreatmentofbreastcancer.Substantialevidence
suggests that this rodent model system mimics human breast
cancer: the initiation of cancer occurs primarily at the same
site in both humans and rats, the majority of the tumors
express estrogen and progesterone receptors, and tumor
development is dependent on the reproductive history, diet,
and hormonal milieu [8]. Thus the model provides an
opportunity to examine cause-and-eﬀect relationships of the
in situ environment fully impacted by systemic factors [9].
17α-ethynyl-5α-androstane-3α,1 7 β-diol (HE3235) is a
synthetic androstane derivative that inhibits 5-androstene-
diol [10], testosterone, and estrogen (unpublished) stim-
ulated prostate cancer cell line (LNCaP) proliferation and
was thus selected as preclinical candidate for evaluation
against hormone sensitive breast cancer. A well-deﬁned
molecular basis for the apparent mechanism(s) of action
of HE3235 has not been elucidated. In human prostate
cancer xenografts, HE3235 does not transactivate the
androgen receptor (AR) and does not antagonize the action
of testosterone on AR, but stimulates the androgen response
element and PSA expression while decreasing AR expression,2 International Journal of Breast Cancer
inducing apoptosis, and inhibiting androgen synthesis
[10, 11]. The pharmacological characteristics of HE3235,
includingthenuclearhormoneinteractionproﬁleofHE3235
and its major metabolites have been published [12]. HE3235
and metabolites 17α-ethynyl-5α-androstane-3β,1 7 β-diol,
and 17α-ethynyl-17β-hydroxy-5α-androstan-3-one, are not
potent sex hormones compared to estradiol and testosterone
b u th a v et h ep o t e n t i a lt ob i n da n dt r a n s a c t i v a t eA R ,e s t r o g e n
receptor alpha (ERα), and estrogen receptor beta (ERβ)
to various degrees, providing the potential for complex
interactions in cells that possess nuclear and/or membrane
receptors for sex steroids. In rodent and canine toxicology
studies, HE3235 was generally well tolerated, with anorexia
emerging at high dose in both species [12].
After conducting pilot experiments in the MNU rat
mammary tumor model that indicated antitumor activity,
we evaluated HE3235 as a single agent and in combination
with docetaxel on tumor growth and response durability
after treatment cessation. We report here that HE3235 in
the rat MNU mammary cancer model exhibits a potent and
durable antitumor activity, which in our hands was superior
to anastrozole and docetaxel and was not accompanied by
apparenttoxicity.The combination ofHE3235and docetaxel
did not synergize toxicity, and the antitumor activity was
found to be superior to tamoxifen monotherapy. These data
provide a rationale to continue investigation of this novel
drug for the potential treatment of hormone-sensitive breast
cancer.
2.Materialsand Methods
2.1. Carcinogenesis. All animal procedures were conducted
at Texas Tech University Health Sciences Center. The proce-
dures were approved by the Health Sciences Center’s Animal
Care and Use Committee and were performed in accordance
with federal and local regulations. Virgin Lewis rats were
purchased from Harlan Sprague Dawley (Indianapolis, IN
and San Diego, CA). The rats were housed in a temperature-
controlled room with a 12-hour light and dark schedule
and fed a standard lab diet with access to food and water
ad libitum. At seven weeks of age, all rats were treated
with a single intraperitoneal (IP) injection of 50mg/kg N-
methyl-N-nitrosourea (Sigma, St. Louis, MO) as previously
described [13, 14].
2.2. Formulationof Test Compounds and DrugTreatment Reg-
imens. When the rats developed palpable tumors (approxi-
mately 5mm × 5mm, 90daysafter MNU)they were divided
into seven treatment groups of thirteen animals each: (1)
Control, (2) 6.6mg HE3235 (high-dose HE3235), (3) 4mg
HE3235(low-doseHE3235),(4)high-doseHE3235+1.5mg
docetaxel, (5) 1.5mg docetaxel, (6) 2.5mg anastrazole, and
(7) 0.25mg tamoxifen. Additional groups of animals were
treated for two weeks with either vehicle or 6.6mg HE3235
(N = 10/group) for purposes of the histopathology evalua-
tion, immunohistochemical staining, and gene expression.
The doses of HE3235 were selected after conducting 28-
day treatment experiments in female rats with established
MNU tumors with 4 and 8mg HE3235 per day. A complete
dose titration toidentify anoptimal dose was not conducted.
The intended high dose for the current study was 8 mg per
day, but analysis of the test article indicated only 6.6mg
was achieved. Docetaxel was selected as a model taxane for
combination therapy with HE3235 because of the common
useoftaxanesinbreast cancermanagement andthepotential
for additive or synergistic activity from agents with diﬀerent
mechanisms of action.
Aqueous solutions of HE3235 were prepared with β-
cyclodextrin sulfobutyl ether (Captisol, CyDex, Lenexa,
Kansas). 17α-Ethynyl-5α-androstane-3α,1 7 β-diol (HE3235)
(Hollis-Eden Pharmaceuticals, San Diego, CA) was formu-
lated asasolutionofeither20 or33mg/mL in30%cyclodex-
trin(w/v).HE3235wasadministered dailybyintraperitoneal
injection (IP) for 4 weeks (4 or 6.6mg, 1mL/kg). HE3235
treatment was combined with docetaxel by contemporane-
ous injection of separate test articles. Docetaxel (Taxotere,
NationalDrugCode0075-8001-20,Sanoﬁ-AventisU.S.LLC)
was serially diluted with 13% aqueous ethanol and 0.9%
saline according to the manufacturer’s instructions to yield
a 0.74mg/mL solution, which was used immediately after
preparation. Two milliliters of diluted docetaxel in saline
(1.5mg, 6mg/kg, 8.1mL/kg) were administered by IP injec-
tion once weekly for four weeks. Anastrazole (AK Scientiﬁc,
Inc, Mountain View, CA) was prepared as a 10mg/mL
solution in 30% aqueous cyclodextrin and administered
daily by IP injection (2.5mg/day; 1mL/kg) for four weeks.
Tamoxifen (free base, Tocris BioScience, Ellisville, Mo)
was prepared as a 1.25mg/mL solution in olive oil, and
administered by subcutaneous injection (SC) once weekly
(0.25mg,1mg/kg,0.8mL/kg)forfourweeks.Vehicle-treated
animals received 1mL/kg 30% aqueous cyclodextrin daily
for 4 weeks. The aqueous ethanol and olive oil vehicles used
for docetaxel and tamoxifen, respectively, were administered
only once per week and were assumed to have minimal
p o t e n t i a lt oa ﬀect tumor growth.
2.3. Tumor Volume Measurements. Animals were palpated
twiceweeklybeginningonemonthaftercarcinogenexposure
until the end of the experiment to monitor mammary
cancer development. Tumor dimensions of length (r1)a n d
width (r2) were measured with a vernier caliper, and tumor
volumeswereestimatedwiththeformulaV = (4π/3)∗r2
1∗r2
(mm3)[ 15]. The histopathology of paraﬃns e c t i o n sw a s
examined from one subset of animals (treated for 2 weeks)
to conﬁrm the carcinomatous nature of the palpable cancers.
2.4. Immunohistochemistry. A f t e rt w ow e e k so ft r e a t m e n t
(vehicle or 6.6mg HE3235) and after conﬁrmation of the
carcinomatous nature of the samples, the tumor sections
were stained for poly(ADP-ribose) polymerase (PARP) and
estrogen receptor alpha (ERα) expression using standard
immunohistochemistry techniques. Cell nuclei were coun-
terstained with Mayer’s hematoxylin (Sigma) and examined
bylightmicroscopy.The percentageofpositivelystainedcells
was determined by dividing the number of positively stained
cells by the total number of cells counted and multiplied by
100.International Journal of Breast Cancer 3
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Figure 1: % Survival. Seven-week-old female Lewis rats were treated with a single IP injection of 50mg/kg MNU. Tumors developed for 90
days, prior to treatment (n = 13) for 28 days with (a) cyclodextrin vehicle daily, (b) 6.6mg HE3235 daily, (c) 4mg HE3235 daily, (d) 6.6mg
HE3235daily+1.5mgdocetaxel weekly, (e)1.5mgdocetaxel weekly,(f)2.5mganastrazoledaily,and(g)0.25mgtamoxifenweekly. HE3235
in combination with docetaxel was more eﬀective than comparator monotherapies at promoting survival. Y-axis, percent survival; X-axis,
study day. Therapy (Tx) started on Day 101 and ended on Day 128. The ﬁrst animal was sacriﬁced on day 139 (vehicle group). ∗P = .0149
versus docetaxel on day 195.4 International Journal of Breast Cancer
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Figure 2: Tumor volume in response to treatment. Seven-week-
old female Lewis rats were treated with a single IP injection of
50mg/kg MNU. Tumors developed for 90 days, prior to treatment
(n = 13) for 28 days with (1) cyclodextrin vehicle daily, (2) 6.6mg
HE3235 daily, (3) 4mg HE3235 daily, (4) 6.6mg HE3235 daily +
1.5mg docetaxel weekly, (5) 1.5mg docetaxel weekly, (6) 2.5mg
anastrazole daily, and (7) 0.25mg tamoxifen weekly. HE3235 in
combination with docetaxel was more eﬀective than comparator
monotherapies at decreasing the mean tumor volume per animal.
Upper graph, all results plotted full scale; lower graph, split and
expanded Y-axis. Anastrazole results were similar to docetaxel, but
not plotted to improve clarity. The mean tumor volume for vehicle
on day 101 was 0.41cm3, which was not plotted to improve clarity.
Tax, docetaxel, Tam, tamoxifen.
2.5. Real-Time PCR. A small set of genes relevant to cell
proliferation, apoptosis, and metastatic potential was quan-
tiﬁed by RT-PCR: amphiregulin (Areg), androgen receptor
(AR), tumor protein 53 (p53), Bcl2 antagonist of cell death
(Bad),apoptosisregulatorBAX(bax),B-cellCLL/lymphoma
2 (Bcl-2), caspase 3 (Casp3), caspase 8 (Casp8), caspase 9
(Casp9), Cyclin D1 (Ccnd1), estrogen receptor alpha (ERα),
estrogen receptor beta (ERβ), progesterone receptor isoform
A (PR-A), vascular endothelial growth factor (VEGF), and
β-actin. Total RNA was extracted from the frozen tis-
sues using a guanidinium thiocyanate-phenol-chloroform
extraction procedure and treated with DNAse [16]. RTPCR
was performed on triplicate samples, using the QuantiTect
Reverse Transcription Kit (Qiagen, Valencia, CA) according
to the manufacturer’s recommendations, and the relative
quantitation of gene expression was calculated using the
comparative Ct method [17]. Data are expressed as the mean
fold diﬀerences compared to vehicle controls normalized to
β-actin expression.
2.6. Statistical Methods. The signiﬁcance of diﬀerences be-
tween means orpaired valueswere calculatedusing Student’s
t-test. Tumor volumes censored for death used the last
observation carried forward (LOCF) for the purpose of data
analysis. The signiﬁcance of treatment eﬀects on animal
survival was determined by Fisher’s exact test using SAS
software (Cary, NC).
3.Results
The high dose of HE3235 and HE3235 in combination with
docetaxel signiﬁcantly inhibited tumor growth without
apparent signs of toxicity. HE3235 in combination with
docetaxel was superior to all other treatments. No animals
treated with the combination of HE3235 plus docetaxel were
sacriﬁced because of tumor burden (P = .0149 versus
docetaxel alone); one animal was sacriﬁced in each of the
groups treated with high or low-dose HE3235 monotherapy
or tamoxifen (P = .073 versus docetaxel alone); six were
sacriﬁced in the docetaxelgroup and seven in the anastrozole
group; all animals were sacriﬁced in the vehicle group
(Figure 1).
All animals had at least one palpable tumor at initiation
of therapy. On the ﬁrst day oftreatment (Day101), the mean
tumor volume was 0.38 ± 0.05mm3 (range 0.31mm3 (anas-
trazole group) to 0.46mm3 (high-dose HE3235-docetaxel
combination)). Tumors in vehicle-treated animals grew
rapidly, with animals sacriﬁced for humane reasons in
this group beginning on Day 139, and the last animal
euthanized on Day 153. Consistent with a pilot experiment,
treatment with high-dose HE3235 alone had a rapid and
potent antitumor eﬀect as indicated by a steep decline in
the tumor volume after initiation of treatment (Figure 2).
The cytoreductive activity of all active treatment groups
was similar for the ﬁrst two weeks of therapy, but the
tumor ablative activity of low-dose HE3235, docetaxel, and
anastrazole waned during the second half of the treatment
period. In addition, tumor volume increased substantially
in the docetaxel and anastrazole groups during the obser-
vation period after treatment cessation. None of these three
treatments showed statistically signiﬁcant antitumor activity
at the end of the treatment period compared to treatment
initiation (P>. 1). In all three instances, treatment appeared
to be more eﬀective in reducing or eliminating small
tumors, while larger tumors were generally more resistant.
In contrast, high-dose HE3235 (P = .011) or tamoxifenInternational Journal of Breast Cancer 5
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Figure 3: Tumor Incidence. Seven-week-old female Lewis rats were treated with a single IP injection of 50mg/kg MNU. Tumors developed
for 90 days, prior to treatment (n = 13) for 28 days with (1) cyclodextrin vehicle daily, (2) 6.6mg HE3235 daily, (3) 4mg HE3235 daily,
(4) 6.6mg HE3235 daily + 1.5mg docetaxel weekly, (5) 1.5mg docetaxel weekly, (6) 2.5mg anastrazole daily, and (7) 0.25mg tamoxifen
weekly. HE3235 as a monotherapy or in combination with docetaxel, was more eﬀective at decreasing the number of tumors and rendering
animalsdisease-free, than comparatortherapies. (a) the eﬀect oftreatment onthe averagenumber oftumors per animal. ∗P start versus end
of treatment = .0008 (6.6mg HE3235), .0007 (4mg HE3235), and <.0001 (HE3235+Tax); §P end of treatment versus end of study = .0003
(Tax), .0016 (Ana), <.0001 (Tam). (b) the percentage of rats in each group without palpable tumors. (there were no disease-free animals in
the vehicle group, not plotted.). ∗∗P versus HE3235 + Tax, <.0001, ∗∗P versus HE3235 + Tax, .0405. Tax, docetaxel; Ana, anastrozole; Tam,
tamoxifen.
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Figure 4: % Tumor cells positive for ERα and PARP. Seven-week-
old female Lewis rats were treated with a single IP injection of
50mg/kg MNU. Tumors developed for 90 days, prior to treatment
(n = 10) for 14 days with cyclodextrin vehicle daily, or 6.6mg
HE3235 daily. Paraﬃn sections of tumors were examined for
histopathology and stained for immunohistochemistry with anti-
bodiestoPARPorER.HE3235treatmentincreasedthefrequency of
cells staining positive for the apoptotic maker, PARP, and decreased
the frequency of ERα, which is associated with tumor survival.
∗P<. 0001.
(P = .0042) aggressively ablated tumor volume through the
end of the treatment period, with a modest volume increase
duringtheobservationperiod.High-doseHE3235combined
with docetaxel prevented tumor growth through the last day
of observation (Day 195) and was more eﬀective at the end
of treatment than either agent used separately (P = .0113
versus high-dose HE3235 and P = .0390 versus docetaxel).
The mean tumor burden in the combination therapy group
was not signiﬁcantly diﬀerent from tamoxifen at the end of
treatment(P = .3451)orattheendoftheobservationperiod
(P = .1383).
Therelativeeﬀectivenessofeachtreatmentwasscoredfor
tumorincidenceattreatmentendandstudyendcomparedto
baseline (Figure 3). Tumor incidence increased dramatically
(from 1.23 to 4.31, P = .0001) in the vehicle-treated-group
during the dosing period (Day 101 to 128) and, as expected,
decreased in response to all active treatments (P<. 05).
Tumor incidence in the monotherapy groups was not
signiﬁcantly higher than the HE3235-docetaxel combination
at treatment end, except for docetaxel (P<. 0089). After
cessation of dosing, tumor incidence increased sharply in
the docetaxel (0.92 to 2.1, P = .0051) and anastrazole (0.69
to 1.77, P = .0051) groups and increased slightly in the
tamoxifen group (0.15 to 0.77, P = .0362), while the tumor
incidence with HE3235 monotherapy or docetaxel combi-
nation continued to decline, although not statistically lower
than at treatment end.
The incidence of disease-free animals in the HE3235 and
tamoxifen groups was comparable at treatment end. Eight
tamoxifen rats were disease free, compared to six and seven
in the low- and high-dose HE3235 groups respectively, and
ten in the HE3235-docetaxel group (Figure 3). At the end of
the observation period, tumor incidence increased by two
in the tamoxifen group (6 of 13 animals were disease free),
whereas tumor incidence decreased by two in the low-dose
HE3235group (8 of13),one in the high-dose HE3235group
(8 of 13), and one in the HE3235-docetaxel group (11 of 13,6 International Journal of Breast Cancer
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Figure 5: Expression of proapoptosis and diﬀerentiation genes in
tumors.Seven-week-oldfemaleLewisratswere treated withasingle
IPinjection of50mg/kgMNU. Tumorsdeveloped for90days,prior
to treatment (n = 10) for 14 days with cyclodextrin vehicle daily,
or 6.6mg HE3235 daily. Gene expression was measured by RT-
PCR.ThegraphsshowratiosofgeneexpressioninHE3235(6.6mg)
treated tumor samples relative to vehicle treated, normalized to β-
actin.Amphiregulin (Areg),androgenreceptor(AR),tumorprotein
53 (p53), Bcl2 antagonist of cell death (Bad), apoptosis regulator
BAX (bax), B-cell CLL/lymphoma 2 (Bcl-2), caspase 3 (Casp3),
caspase 8 (Casp8), caspase 9 (Casp9), Cyclin D1 (Ccnd1), estrogen
receptor alpha (ERα), estrogen receptor beta (ERβ), progesterone
receptor isoform A (PR-A), and vascular endothelial growth factor
(VEGF). HE3235 treatment upregulates proapoptotic genes in
tumors and downregulates tumor proliferation and malignancy
genes.
P = .0405 versus tamoxifen; not signiﬁcant versus high or
low HE3235 monotherapy).
The eﬀectsof HE3235 ontumor tissue were examined by
immunohistochemistry in satellite groupstreated with either
vehicle or high-dose HE3235 for 2 weeks. HE3235 increased
the frequency of PARP stained cells two-fold (2,590 of
3,123 (82.9%) HE3235 treated versus 1,212 of 3,079 (39.4%)
vehicle treated, P<. 0001), and decreased the frequency of
ERα staining approximately 4-fold (603 of 3,058 (19.7%)
HE3235 treated versus 2,349 of 3,051 (77.0%) vehicle
treated, P<. 0001) (Figure 4). The expression of genes
associated with cell proliferation, apoptosis, and metastatic
potential were consistent with the immunohistochemistry
results (Figure 5). Proapoptotic genes were upregulated:
Casp3 (9-fold), Casp8 (11-fold), Casp9 (5-fold), p53 (15-
fold), Bad (13-fold), Bax (10-fold), and ERβ (4-fold), while
genes associated with malignancy, metastasis, and escape
from treatment were downregulated: AR (25-fold), ERα (3-
fold), PR-A (5-fold), and VEGF (4-fold). The expression
of the autocrine growth factor, amphiregulin, and the anti-
apoptotic protein, Bcl-2, were also decreased approximately
4-fold.
4.Discussion
HE3235 is a novel androstane derivative, initially identiﬁed
as an agent to treat prostate cancer. Prior studies with
a hormone sensitive LNCaP cell line demonstrated that
HE3235 could reduce the incidence and development of
androstenediol stimulated xenografts [10]. Using the MNU-
induced rat mammary cancer model, we have shown that
HE3235 is also active against these estrogen-dependent
tumors. This activity appears to be associated with an induc-
tion of apoptosis and suppression of androgen and estrogen
(alpha) nuclear hormone receptor expression. The activity
of HE3235 monotherapy was comparable to tamoxifen and
superior to anastrozole. When combined with docetaxel,
HE3235 was superior to both. No indication of toxicity
was observed from any treatment, and the combination of
HE3235 with docetaxel did not potentiate toxicity. Doses of
comparitor therapies were adapted from previous reports
[18–21]. A pharmacokinetics study estimated the daily
exposure from the 6.6mg dose of HE3235 to be approxi-
mately 12,765ng∗hr/mL, which is similar to the maximum
exposure without severe toxicity (including anorexia) that
was observed in 28-day toxicity studies in rats and many-
fold higher than observed in a Phase I/II prostate cancer
clinical study [12]. HE3235 is orally bioavailable but was
administered parenterally in this study (and in previous
prostate cancer models) to reduce oral cyclodextrin vehicle
eﬀects.
HE3235 aggressively shrank established tumors and pre-
vented the appearance of new tumors. The rate of tumor
volume reduction and degree of tumor suppression after
treatment cessation was similar for high-dose HE3235
monotherapy and tamoxifen. When HE3235 was combined
with docetaxel, not only was the tumor-ablative activity
enhanced, but tumor suppression was also maintained for
sixty daysafter treatment cessation. The potential for tumors
to re-emerge in these animals was not determined, but this
does not diminish the implication of a substantial increase in
apparent disease-free survival.
HE3235 and its major metabolites, 17α-ethynyl-5α-
androstane-3β,1 7 β-diol, and 17α-ethynyl-17β-hydroxy-5α-
androstan-3-one, act as binding and/or transcriptional ago-
nists and antagonists of AR, PR, ERα,a n dE R β nuclear
hormone receptors in vitro [12]. The pharmacology of
HE3235 and its metabolites in sex hormone-dependent
cancers is complex. HE3235 inhibits both androgen- and
estrogen-induced proliferation of LNCaP cells but does
not appear to interfere with androgen response element
(ARE) transcription [10]. Mechanistically, this does not
exclude the possibility that HE3235 and metabolites also
interact with signal transduction pathways mediated by
cell surface receptors. Development of a weak ER agonist
for breast cancer therapy, other than ER-negative variants
such as triple negative breast cancer, must address concerns
regarding the potential for proliferative eﬀects on cancer
cells. Clinical development of HE3235 must be predicated
on the demonstration that proapoptotic eﬀects dominate
potential proliferative eﬀects. Our results in the MNU model
suggest that this indeed occurs, at least in rat mammary
tumors, although further exploration of this issue using
other tumor models may be necessary.
As reported here, HE3235 diminished AR and ERα ex-
pression in the rat MNU model and was previously reported
to decrease AR expression in a hormone-independent
prostate cancer xenograft model [11]. If HE3235 is found toInternational Journal of Breast Cancer 7
beactiveagainst breastcancerinhumans, decreasedERαand
AR expression are associated with improved prognosis and
reduced escape from therapy [22]. HE3235 also decreased
circulating levels of sex steroids in female rats and male dogs
without apparent perturbation of serum gonadotropin con-
centrationsanddecreasedtestosteroneinLuCaP35Vprostate
cancer xenografts in castrated mice [11, 12]. However, the
ability of HE3235 to elicit these activities in humans, and
therelationship ofthese observationsto HE3235’santitumor
activity is not known. Docetaxel, through stabilization of
microtubules [23], and HE3235, by virtue of enhancing the
expression of proapoptotic genes and decreasing expression
of cell survival genes, are both proapoptotic agents, and
as such their combined antitumor eﬀect was enhanced,
although our studies were not designed to demonstrate
synergy. The increased activity of the HE3235-docetaxel
combination could also be explained by a reduction in
endogenous estradiol, since estradiol can reduce taxane-
induced apoptosis through activation of ERK via a plasma
membrane receptor, although other ERK-independent path-
ways may also contribute to these estrogen mediated eﬀects
[24]. Anastrozole is a standard of treatment for reducing
endogenous estradiol in breast cancer patients that failed
ﬁrst-line therapy. Although active in the MNU model,
anastrazole was inferior to HE3235 in our study.
Gene expression assays showed HE3235 increased ex-
pression of proapoptotic genes and decreased expression
of malignancy and tumor survival genes, consistent with
the immunohistochemical analysis and observed eﬀects on
tumor growth. The contrasting eﬀect on the malignancy
promoting genes, AR, PR-A, and ERα (downregulated),
compared to the prodiﬀerentiation maintenance gene, ERβ,
in combination with eﬀects on apoptosis associated genes,
highlights HE3235 as a diﬀerentiation agent, as it induced
programmed cell death in mammary cancer (reported here)
and prostate cancer models [10].
Relative to humans, rodents are known to aggressively
and diﬀerentially metabolize native adrenal steroids [25, 26],
but this was not observed with the synthetic androstanediol
derivative HE3235. In female rats, as in male humans,
the weakly estrogenic HE3235 metabolite, 17α-ethynyl-
5α-androstane-3β,1 7 β-diol, and metabolite, 17α-ethynyl-
17β-hydroxy-5α-androstan-3-one are present in relatively
low abundance in plasma [12]. Furthermore, HE3235 is
the dominant unconjugated molecular species in rats and
humans, decreasing concern that the active molecular
entity in the preclinical model will not be present in the
clinical setting. The half-life of elimination in humans is
approximately 14 hours, which is compatible with both QD
and BID administration schedules; however, the half-life
is only about 1-2 hours in mice or Lewis rats [12]. This
disparity between the preclinical rat model and humans
necessitates the use of disproportionally high doses in rodent
models tocompensate for the rapid elimination compared to
humans.
Many diﬀerent approaches are being used by clinical
and experimental investigators to study prevention and
treatment of breast cancer. Currently there are only three
acceptedtreatments forbreast cancerpreventionin high-risk
females: ovarian ablation, total mastectomy/lumpectomy,
and prolonged treatment with tamoxifen. None of these
are universally acceptable due to the associated physical,
psychological, and physiological side eﬀects. As far as breast
cancer treatment is concerned, the options are based on the
phenotypic proﬁle of nuclear sex hormone receptors in the
patient’s tumors (ERα,P R )[ 27]. All treatments currently
used against these targets have signiﬁcant side eﬀects,
and a good share of patients elect to discontinue therapy
[28, 29].
Currently, the third generation oral aromatase inhibitors
are considered to be ideal candidates to either enhance the
activity of tamoxifen or replace it entirely for the prevention
of breast cancer recurrence in postmenopausal women. In
the head-to-head arm of the ATAC (anastrozole, tamoxifen
alone or in combination) trial, at the 100-month analysis,
the disease-free survival advantage for the hormone receptor
positive population was 4.8% in favor of anastrozole over
tamoxifen [30]. Aromatase inhibitors have an overlapping,
but not identical side eﬀect proﬁle to tamoxifen. One of
the most disturbing side eﬀects of aromatase inhibitors is
the emerging eﬀect on bone, with a signiﬁcant increase in
fractures during the course of the ATAC trial, and an earlier
increase in bone density loss, and an even earlier increase
in bone turnover markers [31]. Clearly, new drugs that treat
breast cancerwithout these harmful side eﬀectswould have a
positive impact on the management of this disease.
Signiﬁcantly in the cancer therapy setting, where drugs
are frequently used in combination, HE3235 does not have
appreciable hepatic, hematopoietic, or cardiopulmonary
toxicity at what are currently believed to be cytoreductive
doses [12]. In contrast to anastrozole, HE3235 may have a
positiveeﬀectonbone,asanincreaseinbonemineraldensity
was found relative to vehicle in an intratibial prostate cancer
xenograft study [11]. This may be relevant to breast cancer
considering the high incidence of bone metastases in this
disease [32]. Accordingly, the safety and activity proﬁle of
HE3235thusprovidesa basis foritscombinationwith classic
cytotoxic agents, such as the taxanes. Such combinations
would beexpected toresultincomplementaryantineoplastic
mechanisms, with a reduced incidence of treatment escape.
Breast cancer adjuvant therapy employs various combina-
tionsofanthracyclines,taxanes, and cyclophosphamide[33].
The data presented here suggest that if the activity in rodents
is present in humans, the addition of HE3235 to an adjuvant
treatment regime may signiﬁcantly enhance the therapeutic
beneﬁt. With its favorable nonclinical safety proﬁle and a
novel mechanism of action, HE3235 is an interesting drug
candidate for evaluation against hormone-sensitive breast
cancer.
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